Genetically predicted ankylosing spondylitis increases the risk of heart failure: a Mendelian randomization study

Chennan Liu1,2, Laicheng Wang3, Mei Lin1,2

  • 1Department of Cardiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Insights

Ankylosing spondylitis may causally increase heart failure risk. This link might be partly explained by increased arterial stiffness, suggesting a cardiovascular disease connection.

Area of Science:

  • Rheumatology
  • Cardiology
  • Genetics

Background:

  • Observational studies suggest a link between ankylosing spondylitis and cardiovascular disease (CVD).
  • The causal nature of this association requires further investigation.
  • Mendelian randomization is a suitable method to explore causality.

Purpose of the Study:

  • To investigate the causal relationship between ankylosing spondylitis and the risk of six prevalent cardiovascular diseases.
  • To assess the influence of potential confounding factors on this relationship.

Main Methods:

  • A two-sample Mendelian randomization analysis was performed.
  • Six cardiovascular diseases were examined: hypertension, heart failure, atrial fibrillation, coronary heart disease, myocardial infarction, and peripheral artery disease.
  • Multivariate Mendelian randomization was used to adjust for confounding variables.

Main Results:

  • Genetically predicted ankylosing spondylitis was associated with an increased risk of heart failure (OR=1.02; 95% CI=1.00-1.04; p=0.030).
  • The association remained significant after adjusting for hypertension, diabetes, smoking, BMI, and pulse wave reflection index.
  • The causal link diminished after adjusting for pulse wave peak-to-peak time and arterial stiffness index.

Conclusions:

  • Genetically predicted ankylosing spondylitis increases the risk of heart failure.
  • Arterial stiffness may be a mediating factor in the causal pathway between ankylosing spondylitis and heart failure.
Abstract

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.2K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
40
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
57
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
55
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
41